TocilizumabV1, Istex, Checkpoint, indexHead, Teeft.i

Index : Teeft.i

Les termes de plus forte occurence

950	Rheumatoid arthritis
763	Rheumatoid
650	Arthritis
596	Rheumatology
473	Disease activity
383	Tocilizumab
377	Baseline
303	Remission
303	Internal medicine
248	Rheum
245	Receptor
232	Rituximab
216	Disease duration
214	Arthritis rheum
190	Cytokine
182	Adverse events
172	Methotrexate
170	Rheumatoid arthritis patients
162	Placebo
155	Roche
155	Inadequate response
145	Cohort
144	Idiopathic
138	Median
138	Biologic
134	Progression
133	Radiographic
132	Randomized
132	Japan background
132	Biologics
130	Etanercept
130	Adalimumab
126	Syndrome
126	Monotherapy
125	Abatacept
124	Risk factors
124	Dmards
117	Nagoya
117	Biological agents
114	Clinical trials
111	Pathway
109	Serum levels
108	Healthy controls
107	Peripheral blood
107	Infusion
104	Control group
103	Rheumatic diseases
99	Pharma
98	Rheumatol
98	Lymphocyte
97	Vasculitis
97	Systemic lupus erythematosus
97	Responder
97	Clin
96	Steroid
96	Juvenile idiopathic arthritis
96	Corticosteroid
96	Clinical immunology
95	American college
93	Lesion
93	Clinical features
92	Clinical response
91	Lupus
90	University hospital
90	Radiographic progression
89	Macrophage
89	Clinical remission
89	Autoimmune
87	Pediatric
86	Pfizer
83	Research institute
82	Synovial
82	Inhibitor
81	Ndings
80	Polymorphism
80	Idiopathic arthritis
80	Ankylosing spondylitis
79	Orthopaedic surgery
79	Medication
79	Body mass index
79	Assay
78	Speakers bureau
78	Autoantibody
77	Pathogenesis
77	Other hand
76	Mutation
75	Present study
75	Hospital universitario
75	Biologic agents
74	Tumour
74	Allele
73	Systemic
73	Systematic review
73	Subset
73	Inflammation
72	Psoriatic arthritis
72	Psoriasis
71	Predictor
71	Placebo group
71	Mrna
70	Relapse
70	Monoclonal antibody
70	Disease activity score
70	Diabetes mellitus
69	Neutrophil
69	Hypertension
69	Biomarkers
69	Arteritis
68	Kinase
67	Tumour necrosis factor
67	Phenotype
67	Genotype
67	Endpoint
66	Seoul
66	Growth factor
66	Dendritic cells
66	Clinical characteristics
65	Rheumatoid factor
65	June
65	Important role
65	Immunosuppressive
64	Toxicity
64	Therapy
64	Novartis
64	Lymphoma
64	Guideline
64	Clinical practice
63	Suppl
63	Response rate
63	Infliximab
63	Biopsy
62	Odds ratio
62	Nagoya university graduate school
62	Medical university
62	Japanese patients
62	Giant cell arteritis
62	Abbott
61	Tregs
61	Multivariate analysis
61	Medical sciences
61	Hong kong
61	Combination therapy
61	Apoptosis
60	Vegf
60	Saitama
60	Randomised
60	Node
60	Nagasaki
60	Joint destruction
60	Immunol
60	Immune
60	Eular
60	East hanover
60	Biologic therapy
60	Active disease
59	Murine
59	Malignancy
59	Elderly patients
59	Clinical symptoms
59	Biological therapy
58	Immunosuppressive therapy
58	Higher risk
58	Elisa
58	Disease severity
58	Departement
58	Comorbidities
58	Allergy
58	Adult patients
57	Viral
57	Symptom
57	Subgroup
57	Serious infections
57	Regimen
57	Medical records
57	Lung disease
57	April
56	Singapore
56	Public health
56	Interstitial lung disease
56	Infection
56	Family history
56	Cardiovascular
56	Abnormality
55	Mrna expression
55	Mediator
55	Joint damage
55	Graduate school
54	Russian federation
54	Protein expression
54	January
54	Foxp3
54	Erythematosus
54	Clinical presentation
54	Chemotherapy
54	Cell proliferation
54	Cdai
54	Cardiac
53	Yokohama
53	States background
53	Smoker
53	Retrospective
53	Clinical course
52	Snp
52	Multivariate
52	Multicenter
52	Metastatic
52	Inflammatory
52	Erythrocyte sedimentation rate
52	Dmard
52	December
52	Autoimmune diseases
51	Tumor necrosis factor
51	Radiological
51	Pulmonary hypertension
51	Prognostic
51	Prognostic factors
51	Postoperative
51	Nodule
51	Msc
51	Morbidity
51	Medical center
51	Critical role
51	Cessation
50	Western blot
50	Surgical
50	Smoking status
50	Renal
50	Recurrence
50	Phosphorylation
50	Neutropenia
50	Infectious diseases
50	Effusion
50	Clinician
50	Brosis
50	Asthma
50	Antibiotic
49	Treatment groups
49	September
49	Oncology
49	October
49	Igg4
49	Health status
49	Epithelial
49	Egfr
49	Disclosure
49	Bevacizumab
49	Baseline characteristics
49	Aortic
49	2department
48	University school
48	Thrombocytopenia
48	Software
48	Smoking cessation
48	Sapporo
48	Poor prognosis
48	Pneumococcal
48	Physical function
48	Malignant
48	Histological
48	Extracellular
48	Exact test
48	Concomitant
48	China background
48	Carcinoma
48	3department
47	Univariate
47	Response rates
47	Refractory
47	Pathogen
47	Normal subjects
47	Nephritis
47	Nding
47	Mmhg
47	Metastasis
47	Mellitus
47	Laser
47	July
47	Discontinuation
47	Diagnosis
47	Comorbidity
46	Therapeutic efficacy
46	Stenosis
46	Retrospectively
46	Radiology
46	Polymerase chain reaction
46	Patient
46	National center
46	Hazard ratio
46	Epithelial cells
46	Emergency department
46	Diagnostic value
46	Copd
46	Biomedical
46	Asymptomatic
46	Allergic
45	Treatment difference
45	Tomography
45	Thoracic
45	Taipei
45	Rheumatology unit
45	Pulmonary disease
45	Pneumonia
45	Nitric
45	Kinki
45	Inhaled
45	Hypoxia
45	Environmental health
45	Brinogen
45	Antirheumatic drugs
45	Antimicrobial
45	Airway
45	4department
44	Xenograft
44	Tohoku
44	Systemic sclerosis
44	Synovitis
44	Standard therapy
44	Squibb
44	Shanghai
44	Respiratory medicine
44	Respiratory failure
44	Respiratory disease
44	Quezon city
44	Pten
44	Primary endpoint
44	Pleural effusion
44	Permeability
44	Patient safety
44	Overall survival
44	Nitric oxide
44	Neutrophilic
44	Murine model
44	Mediastinal
44	Median value
44	Lung function
44	Logistic regression model
44	Kanazawa
44	Ishikawa
44	Interstitial pneumonia
44	Inhaler
44	Hokkaido
44	Hiroshi
44	Hematologic
44	Genetic variations
44	Fukuoka
44	Exon
44	Cyst
44	Cell lung cancer
44	Biochemistry
44	Benign
44	Autophagy
44	Attenuated
44	Atopic
44	Aspergillus
44	Apap
44	Acute exacerbation
44	5department
43	Varenicline
43	Treatment outcome
43	Tiotropium
43	Thymoma
43	Thoracic surgery
43	Takashi
43	Surgical lung biopsy
43	Smoking history
43	Sendai
43	Satoshi
43	Rifampicin
43	Rescue medication
43	Quezon
43	Pulmonary fibrosis
43	Pulmonary artery pressure
43	Prospective cohort study
43	Prognostic score
43	Previous study
43	Pneumothorax
43	Pneumonitis
43	Paclitaxel
43	Obstructive
43	Obstruction
43	Nsclc
43	Niigata
43	Nihon university school
43	Negative patients
43	Mpap
43	Methods patients
43	Lung diseases
43	Linezolid
43	Laba
43	Kyushu
43	Kazuo
43	Kanagawa
43	Juntendo university graduate school
43	Japan introduction
43	Intensive care unit
43	Indonesia background
43	Hiroaki
43	Guangzhou
43	General hospital
43	Fractalkine
43	Exacerbation
43	Dyspnea
43	Docetaxel
43	Critical care
43	Correlated
43	Copd exacerbations
43	Clinical records
43	Cisplatin
43	Certolizumab pegol
43	Bronchodilator
43	Bronchiectasis
43	Asthmatic
43	Asian society
43	Ards
43	Allergic diseases
43	Allergen
43	Aichi
43	2division
42	Zinger officinale
42	Yuji
42	Yoshinori
42	Yoko
42	Xiangya
42	Xiangya hospital
42	Wind speed
42	Waterpipe
42	Watanabe1
42	Wang1
42	Wakayama
42	Ventilator
42	Urokinase intrathoracic infusion therapy
42	Universitas
42	Universitas indonesia
42	Uncontrolled asthma
42	Tuberculosis
42	Trough fev1
42	Transbronchial
42	Tranilast
42	Traffic policemen
42	Tracheal
42	Tosei
42	Toru
42	Tissue disorder
42	Thoracoscopy
42	Tetsuya
42	Terminal stage
42	Tblb
42	Tapse
42	Takeshi
42	Takahashi1
42	Surfactant
42	Surabaya
42	Stent
42	Stc1
42	Sputum
42	Sputum smear
42	Spo2
42	Spirometry
42	Social isolation
42	Smoking
42	Smear
42	Small cell lung cancer
42	Slipa
42	Shiga
42	Shenyang
42	Sgrq
42	Sdai
42	Salmeterol
42	Rsbi
42	Rpob gene
42	Rhinitis
42	Results patients
42	Respirology
42	Respiratory
42	Respiratory rate
42	Respiratory questionnaire
42	Respiratory hospitalization
42	Respiratory diseases
42	Respiratory death
42	Respiratory center
42	Reactance
42	Rassf1a
42	Pulse oximeter
42	Pulmonology
42	Pulmonary tuberculosis
42	Pulmonary medicine
42	Pulmonary function
42	Pulmonary function test
42	Pulmonary complications
42	Prognostic factor
42	Prognosis
42	Ppls
42	Ppfe
42	Portable polygraph
42	Poph
42	Polygraph
42	Pneumonia cases
42	Pmdi
42	Plms
42	Pleural effusions

Manipulations en shell (Unix/Dilib)

HfdCat /Users/jacquesducloy/Documents/WicriRoot/Wicri/Sante/explor/Tocilizumab.storage/TocilizumabV1/Data/Istex/Checkpoint/Teeft.i.hfd| SxmlCut idx/l | grep ...

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021

	Serveur d'exploration Tocilizumab - Checkpoint (Istex) Index « Teeft.i » - tête de navigation
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Tocilizumab - Checkpoint (Istex)Index « Teeft.i » - tête de navigation

Index : Teeft.i

Les termes de plus forte occurence

Manipulations en shell (Unix/Dilib)

Serveur d'exploration Tocilizumab - Checkpoint (Istex)

Index « Teeft.i » - tête de navigation